Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Cecile Lescrainier"'
Autor:
Leila Belkhir, Kevin-Alexandre Delongie, Pierre Wallemacq, Veerle Verlinden, Xavier Wittebole, Cecile Lescrainier, Jamila Hamdani, Flora T. Musuamba, Rakan Nasreddine, Martin Vandeputte, Pauline Thémans, Francoise Wuillaume, Julien De Greef, Jean-Michel Dogné, Nicolas Dauby, Jean-Cyr Yombi, Sophie Kiridis
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Thémans, P, Belkhir, L, Dauby, N, Yombi, J C, De Greef, J, Delongie, K A, Vandeputte, M, Nasreddine, R, Wittebole, X, Wuillaume, F, Lescrainier, C, Verlinden, V, Kiridis, S, Dogné, J M, Hamdani, J, Wallemacq, P & Musuamba Tshinanu, F 2020, ' Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients : Implications for Dose Optimization ', European Journal of Drug Metabolism and Pharmacokinetics, vol. 45, no. 6, pp. 703-713 . https://doi.org/10.1007/s13318-020-00648-y
European journal of drug metabolism and pharmacokinetics, Vol. 45, no.6, p. 703-713 (2020)
European journal of drug metabolism and pharmacokinetics, 45 (6
Thémans, P, Belkhir, L, Dauby, N, Yombi, J C, De Greef, J, Delongie, K A, Vandeputte, M, Nasreddine, R, Wittebole, X, Wuillaume, F, Lescrainier, C, Verlinden, V, Kiridis, S, Dogné, J M, Hamdani, J, Wallemacq, P & Musuamba Tshinanu, F 2020, ' Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients : Implications for Dose Optimization ', European Journal of Drug Metabolism and Pharmacokinetics, vol. 45, no. 6, pp. 703-713 . https://doi.org/10.1007/s13318-020-00648-y
European journal of drug metabolism and pharmacokinetics, Vol. 45, no.6, p. 703-713 (2020)
European journal of drug metabolism and pharmacokinetics, 45 (6
Background and Objective: In the absence of characterization on pharmacokinetics and reference concentrations for hydroxychloroquine in COVID-19 patients, the dose and treatment duration for hydrochloroquine are currently empirical, mainly based on i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3204e0996e3ebcf3d92d43467f2b3ef1
http://europepmc.org/articles/PMC7511144
http://europepmc.org/articles/PMC7511144
Autor:
Deborah Konopnicki, Veerle Verlinden, Francoise Wuillaume, Cecile Lescrainier, Rakan Nasreddine, Marie-Christine Payen, Pauline Thémans, Nicolas Dauby, Jamila Hamdani, Faustine Lebout, Flora T. Musuamba, Jean-Michel Dogné, Marc Delforge, Agnès Libois, Loïc Schrooyen
Publikováno v:
British journal of clinical pharmacology
British Journal of Clinical Pharmacology
Thémans, P, Dauby, N, Schrooyen, L, Lebout, F, Delforge, M, Nasreddine, R, Libois, A, Payen, M C, Konopnicki, D, Wuillaume, F, Lescrainier, C, Verlinden, V, Dogné, J M, Hamdani, J & Musuamba Tshinanu, F 2021, ' Model informed dosing of hydroxycholoroquine in COVID-19 patients : Learnings from the recent experience, remaining uncertainties and gaps ', British Journal of Clinical Pharmacology, vol. 87, no. 2, pp. 674-682 . https://doi.org/10.1111/bcp.14436
British Journal of Clinical Pharmacology
Thémans, P, Dauby, N, Schrooyen, L, Lebout, F, Delforge, M, Nasreddine, R, Libois, A, Payen, M C, Konopnicki, D, Wuillaume, F, Lescrainier, C, Verlinden, V, Dogné, J M, Hamdani, J & Musuamba Tshinanu, F 2021, ' Model informed dosing of hydroxycholoroquine in COVID-19 patients : Learnings from the recent experience, remaining uncertainties and gaps ', British Journal of Clinical Pharmacology, vol. 87, no. 2, pp. 674-682 . https://doi.org/10.1111/bcp.14436
Aims: In the absence of a commonly agreed dosing protocol based on pharmacokinetic (PK) considerations, the dose and treatment duration for hydroxychloroquine (HCQ) in COVID-19 disease currently vary across national guidelines and clinical study prot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9244520dd821326257e798a57a479584
https://pubmed.ncbi.nlm.nih.gov/32559820
https://pubmed.ncbi.nlm.nih.gov/32559820
Autor:
Stéphanie Pochet, Anne-Sophie Lechon, Cécile Lescrainier, Carine De Vriese, Véronique Mathieu, Jamila Hamdani, Florence Souard
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Cancer patients could combine herbal treatments with their chemotherapy. We consulted VigiBase, a WHO database of individual case safety reports (ICSRs) which archives reports of suspected Adverse Drug Reactions (ADRs) when herbal products a
Externí odkaz:
https://doaj.org/article/d4a0c1b88c714b778e2466111c7d3767